-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2024-517238-16-00
5
2026-01-28
Hypochondroplasia
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2024-517057-27-00
5
2026-01-20
patients scheduled to undergo elective surgical procedures with genera
-
2024-516471-33-00
4
2026-01-19
Alport Syndrome
-
2024-519798-20-00
4
2026-01-15
pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)
-
2024-520208-25-00
4
2026-01-15
Still’s disease
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2024-519829-38-00
5
2026-01-09
Heart failure due to systemic left ventricular systolic dysfunction
-
2025-522862-58-00
5
2026-01-09
Locally advanced unresectable or metastatic gastric or gastroesophagea
-
2025-522786-29-00
4
2026-01-07
Spastic Cerebral Palsy
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-518167-35-01
4
2025-12-19
Patients with Metastatic Osteosarcoma
-
2025-521661-27-00
10
2025-12-19
Primary Membranous Nephropathy
-
2025-520825-19-00
5
2025-12-16
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as
Ber
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2025-522452-16-00
4
2025-12-05
Endometriosis related pain
-
2024-512577-27-00
5
2025-12-02
Chronic kidney disease in paediatric patients
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno